Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK‑G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report

21 Dec 2018

Abstract excerpt

Epithelioid inflammatory myofibroblastic sarcoma (EIMS), a specific subtype of inflammatory myofibroblastic tumors (IMT), is a relatively rare malignant mesenchymal tumor with clinical features of positive anaplastic lymphoma kinase (ALK), high invasiveness, treatment resistance and poor prognosis. Therefore, ALK inhibitors represent specific effective drugs for patients with this type of tumor. However, acquired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to IgG4-Related and Inflammatory Diseases
Share to Neuroendocrine Tumor Research Advances
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30675302
DOI: 10.3892/ol.2018.9865

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK‑G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case reportPMID 30675302Read ↗

An Inflammatory Myofibroblastic Tumor With a Novel ALKV1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Semantic proximity Read ↗

Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to CrizotinibSemantic proximity Read ↗

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.Semantic proximity Read ↗

Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic CancerSemantic proximity Read ↗

Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsSemantic proximity Read ↗

ALK-Negative Lung Inflammatory Myofibroblastic Tumor in a Young Adult: a Case Report and Literature Review of Molecular AlterationsSemantic proximity Read ↗

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistanceSemantic proximity Read ↗

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcomaSemantic proximity Read ↗

Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature ReviewSemantic proximity Read ↗

Acquired resistance to crizotinib from a mutation in CD74-ROS1.Semantic proximity Read ↗

A Case Report of RRBP1-ALK Fusion Gene-Positive Epithelioid Inflammatory Myofibroblastic Sarcoma With Collagenous StromaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.